Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Physicians can customize treatment depth and intensity with Avava’s system, improving results for various skin concerns.

JAAD Study Validates Avava’s Precision Laser Innovation

, MD, PhD, MSCI, is a Clinical Associate Professor of Medicine at Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois.

Raj Chovatiya, MD, PhD, MSCI, discusses his approach to diagnosing and treating chronic hand eczema. 

Addressing Diagnostic Ambiguity and Expanding Therapeutic Options in CHE

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Although both methods were well tolerated, enzymatic debridement worked faster in randomized controlled trials.

Enzymatic Debridement Is More Effective than Autolytic for Severe Wounds

Videos

Treatment decisions are increasingly guided by patient values, preferences, and quality-of-life considerations.

The Future of laBCC Treatment with Vishal Patel, MD, FAAD, FACMS

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

The use of cloudbased platforms to send, receive and store patient data in teledermatology adds security risks.

Steps to mitigate cyber risk

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Quality of Life Impact: Supporting Patients With GPP

Panelists discuss how generalized pustular psoriasis (GPP) profoundly impacts patients’ quality of life through physical pain, psychological distress, social isolation, and functional limitations, necessitating comprehensive support systems that address both medical management and psychosocial well-being.

Panelists discuss how IL-17 inhibitors are generally well-tolerated, but common adverse effects include infections, particularly candidiasis, and potential increased suicidal ideation risk. Patients should be informed of candidiasis risk, especially with bimekizumab (Gordon, 2022), and monitored for mood changes, as IL-17s and IL-23s may impact mental health (Blauvelt, 2023). Open discussions help assess risks while ensuring treatment benefits.

Safety Considerations for IL-17 Inhibitorss

Video content above is prompted by the following: 

Now let’s talk about the safety of the IL-17 inhibitor class. What is the overall safety of these agents, and what are some common adverse effects?

How do you talk to your patients about some of the specific adverse events observed with some of these agents such as infections/candidiasis or increased risk of suicidal ideation?

Suicidal ideation risk of IL-17s and IL-23s (Blauvelt, 2023)

Candidiasis recurrence with bimekizumab (Gordon, 2022)

Safety Considerations for IL-17 Inhibitors

Panelists discuss how IL-17 inhibitors are considered for plaque psoriasis based on disease severity, comorbidities, and patient preference. Selection factors include efficacy, safety, access, and cost. Clinical trial data guide choices, but real-world factors impact use. Dosing varies: secukinumab (300 mg weekly for 5 weeks, then monthly), ixekizumab (160 mg at week 0, then 80 mg biweekly for 12 weeks, then monthly), brodalumab (210 mg weekly for 3 weeks, then biweekly), and bimekizumab (320 mg every 4 weeks for 16 weeks, then every 8 weeks). Dosing and device options influence prescribing decisions.

Selecting and Dosing IL-17 Inhibitors in Psoriasis

How do you decide if an IL-17 inhibitor is an appropriate therapeutic option for a patient with plaque psoriasis? What patient factors do you take into consideration?

What factors impact selection of an IL-17 inhibitor for a patient?

How does IL-17 clinical trial data affect your treatment decisions vs real-world factors (access, cost, etc)?

Describe the differences in dosing for the IL-17 inhibitors in psoriasis. Do dosing considerations influence your clinical decision-making when prescribing these agents?

Secukinumab: 300 mg weekly for 5 weeks and then monthly thereafter; option for 150 mg dose in some patients and 2 different device types

Ixekizumab: 160 mg (2 80 mg injections) at week 0, 80 mg every 2 weeks for weeks 2 to 12 and then 80 mg monthly thereafter; 2 different device types

Brodalumab: 210 mg weekly for 3 weeks and then every 2 weeks thereafter

Bimekizumab: 320 mg every 4 weeks for 16 weeks and then every 8 weeks thereafter; consider continuing 320 mg every 4 weeks for patients weighing over 120 kg; 2 different device types in 160 mg or 320 mg doses

Panelists discuss how inhibition of IL-17 in psoriasis treatment significantly improves quality of life by reducing inflammation, skin lesions, itching, and pain. Patients report better psychological well-being, increased social confidence, and improved daily functioning as inflammatory pathways are interrupted.

IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis

How does treatment of psoriasis with an IL-17 inhibitor impact patient quality of life?

Panelists discuss how IL-17 inhibitors are biologics that target the inflammatory cytokine IL-17 pathway. They demonstrate rapid onset of action, with measurable improvement in most patients within 2 to 4 weeks and peak efficacy by 12 to 16 weeks. They achieve high rates of skin clearance in psoriasis patients and maintain efficacy with long-term use.

Clinical Attributes of IL-17 Inhibitors in Psoriasis

What are some of the clinical attributes of IL-17 inhibitors? How quickly do they work in their onset of action, and how do they impact skin clearance?

Joseph E. Guimera

Articles

Latest Updated Articles